CytomX Therapeutics Outlines 2024 Company Priorities and Milestones
- CX-904 (EGFRxCD3 T-cell engager) initial Phase 1a dose escalation data anticipated in the 2nd half of 2024 - - IND...
Cancer
Viracta Therapeutics Provides Clinical Update and Outlook for 2024
Speed to market strategy for Nana-val in patients with relapsed or refractory EBV+ peripheral T-cell lymphoma supported by complete enrollment...
Lisata Therapeutics Announces Publication of Case Report on a Complete Response in a Metastatic Gastroesophageal Adenocarcinoma Patient Treated with LSTA1 in Combination with Standard-of-Care Therapy
LSTA1, the Company’s lead investigational product, in combination with standard-of-care therapy, potentiated a complete response in a patient with metastatic...
Peak Bio, Inc. Awarded Patent with Broad Coverage for Thailanstatin-ADC platform technology (PH-1) a Payload with Novel Immunomodulatory Effects that Target RNA Splicing
Pleasanton, CA, Jan. 04, 2024 (GLOBE NEWSWIRE) -- Peak Bio, Inc. ("Peak Bio" or the "Company") (OTCQB) PK: PKBO), announced that...
4DMT Highlights Recent Clinical Pipeline Progress, Near-Term Milestones and Organizational Updates
Poised for multiple meaningful catalysts in 2024 driven by strong clinical progress across large market programs in wet age-related macular...
First Patient Dosed in Trial Evaluating Efti and the Anti-PD-L1 Therapy BAVENCIO® in Metastatic Urothelial Cancer
Media Release SYDNEY, AUSTRALIA, Jan. 04, 2024 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”),...
Alimera Completes Recruitment for the Synchronicity Study
Study with YUTIQ® has Surpassed Goal of 100 Patients EnrolledATLANTA, Jan. 04, 2024 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq:...
ProPhase poised to ramp up growth at Pharmaloz and Nebula Genomics in 2024
Company also plans to commercialize its BE-Smart Esophageal Cancer Test in 2024Company announces the hiring of long-time industry veteran Jed...
OncoC4 to Present at the 42nd Annual J.P. Morgan Healthcare Conference
ROCKVILLE, Md., Jan. 04, 2024 (GLOBE NEWSWIRE) -- OncoC4, Inc. (“OncoC4”), a late-stage biopharmaceutical company developing novel medicines for cancer,...
Black Diamond Therapeutics Announces Corporate Update and Expected 2024 Milestones
FDA feedback on BDTX-1535 enables initiation of Phase 2 cohort in first-line treatment of non-classical EGFR mutant NSCLC Fast Track...
Quanta Announces IND Clearance by U.S. FDA for QTX3034, G12D-Preferring Multi-KRAS Inhibitor, and Other Pipeline Updates
– First-in-human clinical trial evaluating QTX3034 as monotherapy and combination in patients with KRASG12D-mutated advanced solid tumors to begin in...
IN8bio Highlights Recent Company Accomplishments and Outlines 2024 Pipeline Goals
Presented positive data showing continued durable complete remissions (CR) achieved in 100% of evaluable leukemia patients in Phase 1 investigator-sponsored...
ITM Announces Operational Readiness for NOVA Facility, the World’s Largest Lutetium-177 Production Site
Receipt of Radioactive Material Handling License (RAM License) for production of n.c.a. Lutetium-177Progress demonstrates company’s ability to rapidly increase GMP...
Verrica Pharmaceuticals Announces Receipt of Minutes from Type C Meeting with FDA Regarding Clinical Development of YCANTH™ for the Treatment of Common Warts
WEST CHESTER, Pa., Jan. 04, 2024 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica” or “the Company”) (Nasdaq: VRCA), a dermatology...
Sensei Biotherapeutics Provides Corporate Update and Highlights Key Upcoming Milestones
- Completed SNS-101 monotherapy dose escalation through 15 mg/kg with no dose limiting toxicities - - Expands patient cohort in...
Kiniksa Pharmaceuticals Provides Corporate Update
– ARCALYST® (rilonacept) 2023 net product revenue grew ~90% year-over-year to $233.1 million (unaudited) – – ARCALYST 2024 net product...
Angle PLC Announces Breakthrough Clinical Results
BREAKTHROUGH CLINICAL RESULTS PROVIDE A UNIQUE INSIGHT INTO THE PROGRESSION OF EACH PATIENT'S CANCERCombined DNA Next Generation Sequencing of CTCs...
Gilead Named to Dow Jones Sustainability World Index for Third Consecutive Year
- Gilead Also Included on the Dow Jones Sustainability North America Index; Rankings Reflect Gilead's Ongoing Commitment to Corporate Responsibility...
Carebox and Gastric Cancer Foundation (GCF) Announce the GCF Clinical Trial Finder
Now patients, caregivers and healthcare professionals have an easy and effective way to search for and match with gastric cancer...
Investigator-initiated Phase 1/2 Clinical Trial Using Salarius Pharmaceuticals’ Seclidemstat in Combination with Azacitidine to Treat Hematologic Cancers Resumes Patient Enrollment
Additional Ewing Sarcoma Patient in Company’s Phase 1/2 Sarcoma Trial Achieves Partial Response; Objective Response Rate Among First-Relapse Ewing Patients...